Stockwinners Market Radar for September 05, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:11 EDT Trump tweets NYT must turn over source of today's op-ed for 'national security' - President Donald Trump tweeted: "Does the so-called "Senior Administration Official" really exist, or is it just the Failing New York Times with another phony source? If the GUTLESS anonymous person does indeed exist, the Times must, for National Security purposes, turn him/her over to government at once!"

20:55 EDT Aehr Test Systems to showcase next-gen multi-wafer test system at SEMICON - Aehr Test System announced that it is showcasing its FOX-XP(TM) next generation multi-wafer test and burn-in systems for high volume production and early failure rate test in booth K2032 at SEMICON Taiwan 2018, taking place September 5-7 at the TWTC Nangang Hall Taipei, Taiwan. The key features of the FOX-XP test cell that contribute to the cost-effectiveness of the solution include the ability to provide up to 2,048 "Universal Channels" per wafer or DiePak carrier, which allows the system to test all the devices on the wafer or DiePak carrier in parallel. The innovative "Universal Channel" architecture allows any channel to be any function (I/O, Device Power Supply (DPS) or Per-pin Precision Measurement Unit. This enhanced architecture now allows customers to perform per pin parametric testing, more extensive digital pattern test with deeper data stimulus / capture memory (32M per pin), and deeper scan (768M) optimized for BIST/DFT testing.

19:59 EDT Investa says Blackstone prepared to raise offer to A$5.52 per unit - Investa Listed Funds Management Limited announces that it has received a letter from Blackstone (BX) which states that Blackstone is prepared to increase the consideration payable per Investa Office Fund unit under the Scheme from A$5.3485 to A$5.52 per unit. Investa said its board intends to work with Blackstone to give effect to the price increase. It added, "To the extent that agreement with Blackstone on the price increase can be reached, ILFML intends to seek judicial advice that it is justified in resuming the adjourned meeting and to approve the release of supplementary disclosure. Subject to reaching agreement with Blackstone and receiving judicial advice, it is proposed that the IOF unitholder meeting will take place as soon as practicable."

19:00 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Cloudera (CLDR) up 12.8%... Verint Systems (VRNT) up 10.2%... SeaChange (SEAC) up 6.6%... AeroVironment (AVAV) up 5.1%... Ctrip (CTRP) up 2.8%. DOWN AFTER EARNINGS: REV Group (REVG) down 7.9%... Guidewire (GWRE) down 7.6%... Zscaler (ZS) down 5.6%... DocuSign (DOCU) down 3.3%... MongoDB (MDB) down 2.7%... Ollie's Bargain (OLLI) down 1.1%. ALSO LOWER: ProQR Therapeutics (PRQR) down 11.7% after equity offering... Dicerna Pharma (DRNA) down 2.3% after equity offering.

18:35 EDT Alamos Gold discloses 'significant' increase in resources at Island Gold - Alamos Gold reported an updated National Instrument 43-101 compliant Mineral Reserve and Resource estimate for its Island Gold Mine as of June 30, 2018. This incorporates exploration drilling completed during the first half of 2018, the majority of which was released in the May 24, 2018 exploration update. Proven and Probable Mineral Reserves increased 129,000 ounces before mining depletion. Net of mining depletion, Mineral Reserves increased 8%, or 72,000 ounces, to 959,000 ounces. Mineral Reserve grades increased 5% to 10.69 g/t Au. Measured and Indicated Mineral Resources increased 99%, or 110,000 ounces. Inferred Mineral Resources increased 30%, or 271,000 ounces, to 1,180,000 ounces with grades increasing 5% to 9.99 g/t Au.

18:06 EDT Ctrip up over 4% afterhours following Q2 results

17:37 EDT NetApp VP Joel Reich sells over 7K shares of company stock - NetApp VP Joel Reich disclosed in a filing that he had sold 7,157 shares of company stock at an average price of $86.83 per share on August 31. The total transaction value of the sale was $621,443.

17:26 EDT GAP Airports reports August traffic up 7.4% - During August 2018, GAP Airports total terminal passengers increased 7.4% at the company's 13 airports, compared to the same period of the previous year. Domestic passenger traffic increased by 9.2%, while international passenger traffic increased by 4.8%. GAP registered a 9.6% increase in the number of seats available compared to August 2017. Load factors for the month decreased by 1.5 percentage points, from 83.0% in August 2017 to 81.5% in August 2018.

17:21 EDT Sarissa Capital reports 4.8% stake in Apricus Biosciences

17:12 EDT Perceptive Advisors reports 9.2% passive stake in MEI Pharma

17:08 EDT Northrop Grumman awarded $164.3M and $89.0M U.S. Navy contract modifications - Northrop Grumman Systems is being awarded a $164,326,263 firm-fixed-price modification to a previously awarded, fixed-price-incentive contract. This modification provides for the procurement of one Japan configuration E-2D Advanced Hawkeye aircraft for the government of Japan. Northrop Grumman Systems is also awarded $89,046,682 for modification to increase the ceiling of a previously awarded indefinite-delivery/indefinite-quantity contract for the research and development of AH-1Z and UH-1Y System Configuration Sets mission computers in support of the U. S. Marine Corps. SCS activities include designing, developing, and implementing upgrades to existing mission computer software and ancillary hardware and/or improved functionality and obsolescence management of the mission computer. Other deliverables include system improvement and demonstration products associated with SCS block upgrades to the Integrated Avionics Systems such as proposed prototypes, pre-production products, and support equipment enhancements, or simulations and models of weapon systems.

17:07 EDT Kinder Morgan, EagleClaw to proceed with Permian Highway Pipeline Project - Kinder Morgan Texas Pipeline, a subsidiary of Kinder Morgan(KMI), and EagleClaw Midstream Ventures, a portfolio company of Blackstone Energy Partners, announced a final investment decision to proceed with the Permian Highway Pipeline Project after having executed definitive joint venture agreements and having secured sufficient firm transportation agreements with shippers. Nearly all capacity available on the system is subscribed and committed under long-term, binding transportation agreements. The remaining capacity is expected to be awarded shortly. Shippers that have committed to the project include EagleClaw, Apache, and XTO Energy, a subsidiary of Exxon Mobil Corporation, amongst others. As previously announced, KMTP and EagleClaw will be the initial partners, each with a 50 percent ownership interest in the project. KMTP will build and operate the pipeline. Apache will have the option to acquire equity from the initial partners and has announced its intent to assign that option to Altus Midstream, a new company announced by Apache and Kayne Anderson Acquisition (KAAC) on Aug. 8. KMI's and EagleClaw's ultimate ownership interest may vary between approximately 27% and 50%, depending on the outcome of ownership options held by anchor shippers. The approximately $2Bn PHP Project will provide an outlet for increased natural gas production from the Permian Basin to growing market areas along the Texas Gulf Coast and is designed to transport up to 2 billion cubic feet per day of natural gas through approximately 430 miles of 42-inch pipeline from the Waha to Katy, Texas, areas, with connections to the U.S. Gulf Coast and Mexico markets. The PHP Project is expected to be in service in late 2020, assuming timely receipt of the requisite regulatory approvals.

16:50 EDT Old Dominion reports August LTL tons per day increased 9.7% YoY - Old Dominion Freight Line reported certain less-than-truckload, LTL, operating metrics for August 2018. LTL tons per day increased 9.7% as compared to August 2017, due primarily to a 10.0% increase in LTL shipments per day that was slightly offset by a 0.3% decrease in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight increased 12.0% as compared to the same period last year. Greg C. Gantt, President and CEO of Old Dominion, commented, "Our revenue increased more than 20% for each of the first two months of the third quarter, due to sustained strength in the domestic economy and our continued ability to win market share by delivering superior service at a fair price. Although the rate of our LTL volume growth thus far in the third quarter has been slightly below what we experienced during the first half of the year, we believe this change is primarily attributable to our decision to reduce the number of heavy-weighted shipments in our network. This strategic reduction also had a positive impact on LTL revenue per hundredweight. Customer demand for our service offerings remains strong, and we believe our service center network capacity will remain sufficient to support the anticipated growth of our business for the foreseeable future. We intend to continue to reinvest in our business to ensure that we have the necessary equipment, facilities and people to support our long-term strategic initiatives, which we believe will continue to increase shareholder value."

16:39 EDT Essendant acknowledges receipt of Staples offer - Essendant (ESND) acknowledged receipt of a letter from Staples, Inc (SPLS), including Staples' reiteration of its proposal to acquire Essendant for $11.50 per share in cash. The Essendant Board of Directors, in consultation with its legal and financial advisors and consistent with its fiduciary duties, is reviewing the letter and other materials filed earlier by Staples with the Securities and Exchange Commission. As previously announced, Essendant and Genuine Parts Company (GPC) entered into a definitive merger agreement on April 12, 2018, in which Essendant agreed to combine with GPC's S.P. Richards business. The merger agreement with GPC remains in effect, and the Essendant Board has not changed its recommendation that Essendant's shareholders vote in favor of that transaction. Essendant remains committed to implementing its strategic initiatives as it evolves its business, supports its customers and builds on the momentum reflected in the Company's improved financial results for the second quarter of 2018.

16:28 EDT CBIZ director Donald Weir sells 10K shares of company stock - CBIZ director Donald Weir disclosed in a filing that he had sold 10,000 shares of company stock at an average price of $23.77 per share on August 31. The total transaction value of the sale was $237,747.

16:22 EDT MongoDB reports Q2 subscription revenue up 63% - Q2 MongoDB Atlas revenue was 18% of total Q2 revenue, up over 400% Year-over-Year.

16:18 EDT Starwood Property expands board of directors with appointment of Fred Ridley - Starwood Property has appointed Fred S. Ridley as an independent director to its board of directors, effective immediately. With the addition of Ridley, the board expands to seven members, five of whom are independent. Fred Ridley is a partner with Foley & Lardner LLP. He is the former national chair of Foley's Real Estate Practice, and a member of the Hospitality & Leisure, and Sports Industry Teams. Ridley also is a former member of the firm's Management Committee.

16:14 EDT Cloudera up over 10% afterhours following Q2 earnings and FY19 outlook

16:12 EDT Cloudera reports Q2 subscription revenue up 26% at $93.1M - Subscription revenue represented 84% of total revenue, up from 82% in the second quarter of fiscal 2018 . Non-GAAP subscription gross margin for the quarter was 87%, up from 85% in the second quarter of fiscal 2018. Customers with annual recurring revenue greater than $100,000 were 568, up 30 for the quarter.

16:09 EDT Maxwell partners with SIemens for grid energy storage design-in - Maxwell announced a grid energy storage subsystem design-in with Siemens to deliver grid voltage and frequency support solutions. SVC PLUS FS built by Siemens and enabled by Maxwell Technologies' ultracapacitor solution secures the energy and bridging reserves necessary to provide protection against emergency grid system imbalances.

16:06 EDT RadiSys shareholders approve proposals related to Reliance merger - Radisys Corporation announced that its shareholders have voted to approve proposals related to the previously announced merger agreement under which Radisys will be acquired by Reliance Industries, with over 97% of shares that voted being in favor of the merger. The transaction is expected to close in the fourth quarter of 2018, subject to the satisfaction or waiver of customary closing conditions, including regulatory approvals. Upon the completion of the proposed transaction, Radisys shareholders will be entitled to receive $1.72 in cash per share, subject to the terms of the definitive merger agreement, and Radisys' common stock will no longer be publicly traded and will be delisted from the NASDAQ Global Select Market.

15:33 EDT Nielsen acquires digital games market intelligence firm SuperData Research - Nielsen Holdings announced it has completed its acquisition of SuperData Research, a leading provider of market intelligence on digital games, gaming video content, and virtual/augmented reality across mobile, PC online, console and other digital platforms. The company analyzes the spending of over 160 million paying digital gamers, worldwide.Intelligence provided by SuperData will enhance the industry-leading capabilities of Nielsen Games and Nielsen Esports, tapping into the $109B video gaming industry. SuperData provides custom and syndicated data solutions to clients and tracks the consumption of games-as-media, including esports and gaming streaming content on digital media platforms. Nielsen Games and Nielsen Esports offer unrivaled expertise in a rapidly changing marketplace, innovative technology, and groundbreaking research, analytics and insights for video game publishers, console manufacturers, and media platforms, as well as esports rights holders, brands, and other industry stakeholders around the world. With this acquisition, clients will now have greater access to global market intelligence around digital video gaming use, sales, and audiences, in addition to our existing areas of expertise such as consumer research, video game tracking, esports sponsorship valuation and consulting services.

14:52 EDT Cryptocurrency stocks dive on BI report that Goldman pausing crypto plans - Cryptocurrency stocks fell after Business Insider said, citing sources, that Goldman Sachs is dropping its plan to open a trading desk for cryptocurrencies. Goldman has been looking into developing a new trading group focused on digital currencies such as bitcoin this past year. According to the BI report, Goldman is uncertain about the current regulatory environment. PRICE ACTION: Shares of Bitcoin Investment Trust (GBTC) are down 6%, while Overstock.com (OSTK) is plunging over 10% in afternoon trading. OTHERS: Other shares in the crypto space are falling, including Marathon Patent Group (MARA), DPW Holdings (DPW), and Riot Blockchain (RIOT).

14:12 EDT Lilly say study of flortaucipir PET imaging agent met its two primary endpoints - Eli Lilly and Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly, announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography, PET,imaging agent, met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer's disease diagnosis. The study, referred to as A16, enrolled a total of 156 end-of-life patients with dementia, mild cognitive impairment, or normal cognition who underwent flortaucipir PET imaging. Subsequently, 67 of these patients were evaluated post-mortem. The study met pre-specified endpoints with flortaucipir demonstrating statistically significant sensitivity and specificity for detecting tau pathology of Braak Stage V/VI, a pathological staging scale for tau neurofibrillary tangles. Flortaucipir also demonstrated statistically significant sensitivity and specificity for detecting a high level of total Alzheimer's disease neuropathologic change using the National Institute on Aging and Alzheimer's Association neuropathology criteria. "These encouraging results are a major advance in our ability to image the pathology of Alzheimer's disease," said Mark Mintun, M.D., vice president of Lilly's pain and neurodegeneration research and development. "We hope this and other advances in the field can help speed development of treatments, as well as provide more diagnostic information for doctors taking care of patients suspected of having Alzheimer's." The company plans to disclose more detailed study results in October at the Clinical Trials on Alzheimer's Disease meeting in Barcelona, and will discuss these findings and potential next steps with the U.S. Food and Drug Administration in the near future.

13:40 EDT Nike releases new 'Just Do It' ad featuring Colin Kaepernick - Nike has released, via its official YouTube channel, the first advertisement from its new "Just Do It" campaign. The advertisement features, and is narrated by, Colin Kaepernick, who has drawn criticism for beginning the trend of NFL athletes kneeling or otherwise engaging in acts of protest during the playing of the national anthem before games. Reference Link

13:35 EDT Constellation Brands sees cannabis as $200B business in 'fairly short order' - Constellation Brands president William Newlands said during the Barclays Global Consumer Staples Conference, "Fundamentally, we believe [cannabis] is going to be a big business worldwide... But this is not going to be limited to Canada. This will be undoubtedly a market that develops in the United States, it's already done so on a state-by-state basis here. It's developing around the world, in places like Germany and Australia and other markets. So that the whole combination of things said that this is going to be a big business. We want to bet on who we think will be the winner in this space and the market leader. And we want to bet on a management team and a business strategy and approach that we think is positioned to win. By doing the investment the way we did, we've created an effective war chest for us to be able to invest and for Canopy to be able to invest and whatever markets and categories and sectors of the business that makes sense to take a strong market-leading position around the world in the business that we think could be a $200B business in fairly short order."

13:00 EDT Dick's Sporting names Vidya Jwala Chief eCommerce and Supply Chain Officer - Dick's Sporting Goods (DKS) announced Vidya Jwala has been named Chief eCommerce and Supply Chain Officer. In this role, Jwala will be responsible for the company's digital integration of eCommerce and Supply Chain efforts, and will report to Lauren Hobart, President, DICK'S Sporting Goods. Vidya joins DICK'S from Overstock.com (OSTK), where he most recently served as Senior Vice President of Merchandising, Supply Chain, Technology & Customer Service.

12:35 EDT Voya Financial announces partnership with technology accelerator Plug and Play - Voya Financial announced a partnership with Plug and Play, a global innovation and acceleration platform that connects technology startups with investors and corporate partners who can help them bring their innovative solutions to market. This partnership enables Voya Financial to collaborate with entrepreneurs from around the world who are at the leading edge of digital transformation. As a key partner in Plug and Play's FinTech vertical, Voya Financial will provide ongoing feedback and mentorship support to assist the startups in refining their product offerings and developing their go-to-market strategies.

12:03 EDT EA says "FIFA 18" has sold over 24M copies to date - Electronic Arts (EA) said that since "EA Sports FIFA 18" launched 11 months ago, players "from all over the world have been playing the game more than ever before in franchise history." The company noted that "FIFA 18" has sold over 24M copies to date, and that the "FIFA" franchise continues to be the best-selling sports video game of all-time, with over 260M units sold across the series to date. EA added that "FIFA Ultimate Team" continues to be one of the most popular modes in "FIFA," and "FUT 18" fans have created over 13M clubs within the mode. The "EA SPORTS FIFA 18" Global Series had more than 20M players competing in competitive gaming events across "FIFA 18" and "FIFA Online 3," with players across 60 countries around the world. "FIFA Mobile" has surpassed 193M installs worldwide, and in the recently launched FIFA Mobile game in China fans have played over 900M sessions. The company added that the upcoming entry in the series, "FIFA 19," will be available worldwide September 28 on PlayStation 4 (SNE), Xbox One (MSFT), PC, and Nintendo Switch (NTDOY).

12:00 EDT RH falls -10.1% - RH is down -10.1%, or -$15.21 to $136.07.

12:00 EDT Alliance One rises 6.1% - Alliance One is up 6.1%, or $1.05 to $18.40.

12:00 EDT GameStop rises 13.0% - GameStop is up 13.0%, or $1.82 to $15.87.

11:44 EDT Chicago Capital Management reports 5.2% passive stake in Poage Bankshares

11:23 EDT Tronox to appeal decision on merger injunction, consider remedial divestiture - Tronox commented on the decision by the U.S. District Court for the District of Columbia granting the U. S. Federal Trade Commission's request for a preliminary injunction regarding Tronox's proposed acquisition of Cristal. The company intends to promptly file a notice of appeal and request an expedited hearing of its appeal to reverse the Court's decision so Tronox may proceed with the merger. Simultaneous to its pursuit of an appeal, Tronox will be considering whether to proceed with the remedial divestiture of Cristal's Ashtabula, Ohio, two-plant titanium dioxide production complex. "Tronox is disappointed by the U.S. District Court's decision to further delay this output-enhancing combination designed to increase the supply of TiO2 for North American customers and position Tronox to succeed in a fiercely competitive global market. As we pursue an appeal, Tronox has valuable alternatives to consider, including a possible remedial transaction to divest the Ashtabula facility for $1.1B to Venator or waiting for a decision by the FTC's Administrative Law Judge in the Part 3 Procedure. During the Part 3 Procedure, I believe we convincingly demonstrated that the FTC's objections to the Cristal transaction are entirely misplaced and this highly synergistic transaction will significantly increase production of TiO2 to the benefit of customers in North America and around the world. We intend to be as transparent and open as possible and will be forthcoming with our chosen course of action at the appropriate time," said Tronox CEO Jeffry Quinn.

11:21 EDT Tronox to consider proceeding with remedial divestiture of Cristal TiO2 complex

10:49 EDT Facebook, Twitter under pressure as executives testify before Congress - Sheryl Sandberg, COO of Facebook (FB), and Jack Dorsey, CEO of Twitter (TWTR), are testifying today in front of the Senate Intelligence Committee, which is assessing how well social media companies are confronting foreign influence on their platforms. In her opening remarks, Sandberg reiterated that Facebook was too slow to react in 2016 when the platform was used for election interference by Russian accounts. Meanwhile, Dorsey has tweeted that he is not "proud" of the way its platform has been used to spread propaganda and the way "bad faith actors" were able to "game Twitter." FACEBOOK 'TOO SLOW' TO REACT: In a hearing before the Senate Intelligence Committee today, Facebook executive Sheryl Sandberg acknowledged that the social media giant was too slow to respond to foreign efforts to interfere in the U.S. elections. "We were too slow to spot this and too slow to act. That is on us," she said. "We're getting better at finding and stopping our opponents." DORSEY NOT 'PROUD': Twitter CEO Jack Dorsey posted his opening remarks to a Senate panel on the company's platform as he began issuing the remarks in person. They read in part, "I'm someone of very few words, and typically pretty shy, and I realize how important it is to speak up now. If it's okay with all of you, I'd like to read you something I personally wrote as I considered these issues. I'll also tweet this out now. First, I wanted to step back and share our view of Twitter's role in the world. We believe many people use Twitter as a digital public square...We're extremely proud of helping to increase the accessibility and velocity of a simple, free and open exchange. We believe people will learn faster by being exposed to a wide range of opinions and ideas, and it helps to make our nation, and the world, feel a little bit smaller. We aren't proud of how that free and open exchange has been weaponized and used to distract and divide people, and our nation. We found ourselves unprepared and ill-equipped for the immensity of the problems we've acknowledged....Our interests are aligned with the American people and this committee. If we don't find scalable solutions to the problems we're now seeing, we lose our business, and we continue to threaten the original privilege and liberty we were given to create Twitter in the first place. We weren't expecting any of this when we created Twitter over 12 years ago...We're identifying and challenging 8-10 million suspicious accounts every week. And we're thwarting over a half million accounts from logging in to Twitter every day. We've learned from 2016 and more recently from other nation's elections how to help protect the integrity of our elections. Better tools, stronger policy, and new partnerships are already in place. We intend to understand the efficacy of these measures to continue to get better. But we all have to think a lot bigger, and decades past today...Required changes won't be fast or easy. Today we're committing to the people, and this committee, to do that work, and do it openly." SENATORS BLAST ALPHABET: The Senate Intelligence Committee purposely set up an unoccupied seat for Alphabet (GOOG; GOOGL) as they wanted either CEO Larry Page or Google chief executive Sundar Pichai to testify alongside Twitter's Dorsey and Facebook's Sandberg, but the company offered its top lawyer and SVP of global affairs Kent Walker. "I'm disappointed Google decided against sending the right senior level executive," Senator Richard Burr said in his opening remarks. PRICE ACTION: In morning trading, shares of Facebook have slipped over 1% to $169.16, while Twitter's shares have dropped more than 5% to $33.07. Class A shares of Alphabet have also slid almost 2% to $1,189.08.

10:40 EDT Mercedes says Amazon 'world's largest Sprinter customer' with 20,000 van order - Mercedes-Benz Vans (DDAIF) announced that its new Sprinter plant for the North American market in North Charleston, South Carolina, is now up and running following a two year construction period. To coincide with the opening, Mercedes-Benz Vans also announced it will be producing Amazon-branded Sprinter vans for the retail company's new Delivery Service Partner program at the new plant. Small business owners will work with third-party fleet management companies to procure their customized vans and get special leases in order to keep their startup costs low. "We're proud to partner with Mercedes-Benz Vans to contribute to local economies through the order of Amazon branded Sprinter vans produced at their new plant in North Charleston. Thanks to the tremendous response to Amazon's new Delivery Service Partner program, we are excited to increase our original order of branded Sprinter vans to 20,000 vehicles so new small businesses will have access to a customized fleet to power deliveries of Amazon packages," said Dave Clark, Amazon's (AMZN) Senior Vice President of Worldwide Operations. Reference Link

10:12 EDT Twitter CEO admits to being 'unprepared and ill-equipped' to problems - Twitter CEO Jack Dorsey posted his opening remarks to a Senate panel on Twitter. They read in part, "I'm someone of very few words, and typically pretty shy, and I realize how important it is to speak up now. If it's okay with all of you, I'd like to read you something I personally wrote as I considered these issues. I'll also tweet this out now. First, I wanted to step back and share our view of Twitter's role in the world. We believe many people use Twitter as a digital public square...We're extremely proud of helping to increase the accessibility and velocity of a simple, free and open exchange. We believe people will learn faster by being exposed to a wide range of opinions and ideas, and it helps to make our nation, and the world, feel a little bit smaller. We aren't proud of how that free and open exchange has been weaponized and used to distract and divide people, and our nation. We found ourselves unprepared and ill-equipped for the immensity of the problems we've acknowledged....Our interests are aligned with the American people and this committee. If we don't find scalable solutions to the problems we're now seeing, we lose our business, and we continue to threaten the original privilege and liberty we were given to create Twitter in the first place. We weren't expecting any of this when we created Twitter over 12 years ago...We're identifying and challenging 8-10 million suspicious accounts every week. And we're thwarting over a half million accounts from logging in to Twitter every day. We've learned from 2016 and more recently from other nation's elections how to help protect the integrity of our elections. Better tools, stronger policy, and new partnerships are already in place. We intend to understand the efficacy of these measures to continue to get better. But we all have to think a lot bigger, and decades past today. We must ask the question: 'what is Twitter incentivizing people to do (or not do), and why?' The answers will lead to tectonic shifts in how Twitter, and our industry, operates. Required changes won't be fast or easy. Today we're committing to the people, and this committee, to do that work, and do it openly."

09:52 EDT Wuhan General to focus on cryptocurrency farms after SDT spin-off - Wuhan General Group announced its plan to pursue a spin-off of the Company's Canadian tech-related business, Strategic Development of Technology to company shareholders. The separation is a strategic move by the Company to benefit its shareholders with the enhanced growth potential of two fully reporting parent companies that span multiple fast-developing industries. The transaction is intended to take the form of a tax-free distribution to Wuhan shareholders, who are eligible to receive SDT common stock shares. The distribution ratio and Record Date will be announced at a later time. With SDT as a standalone public company, the spin-off will ensure that Wuhan shareholders will continue to benefit from SDT subsidiaries. Following the transaction, each parent company will have distinct corporate strategies and capital allocation priorities: Wuhan's portfolio of businesses will be comprised primarily of industry-leading blockchain technology development. By isolating its cryptocurrency profile, the Company is expected to generate stable growth opportunities and focus its strategy to acquire and generate business in new industries. The spin-off of the private company Strategic Development of Technology into a public company will be focused on the development of batteries, electric equipment, and Intelligence technology. SDT's subsidiaries have leading positions in industrial mining and energy markets throughout North America. The spin-off transaction will position these three subsidiaries to drive industry growth and initiatives in creating sustainable solutions for these markets. The private company, SDT will undergo an audit during the month of September and then file its initial registration statement with the Securities and Exchange Commission to be a fully reporting company. The Company plans on listing SDT on the OTC Markets OTCQB marketplace first, then on the CSE. Once the separation is complete, Wuhan General Group Inc. will file its three years of audited financials to become a fully reporting company as well as uplisting to OTCQB; the name and ticker change will follow. The Company will continue to provide shareholders with transaction details as they arise. A new corporate website for Wuhan and SDT will go live prior to the Record Date, which will be announced at a later time.

09:47 EDT Tilly's falls -7.3% - Tilly's is down -7.3%, or -$1.84 to $23.30.

09:47 EDT Canopy Growth rises 4.3% - Canopy Growth is up 4.3%, or $2.24 to $54.64.

09:47 EDT Smartsheet rises 6.9% - Smartsheet is up 6.9%, or $2.20 to $33.90.

09:41 EDT Weis Markets mentioned cautiously at Spruce Point Capital

09:30 EDT Energous secures approval for WattUp wireless charging in 100 countries - Energous announced that it has secured regulatory certification for its WattUp Near Field wireless charging technology in 100 countries around the world, including the United States, Australia, Canada, India, Taiwan and the entire European Union. Energous shares are up $1.27, or 10.3%, to $13.60 in pre-market trading.

09:16 EDT Marriott plans to expand branded residential portfolio by over 70% by 2022 - Marriott International announced that its branded residential portfolio is expected to grow by more than 70% in four years as both consumers and residential real estate developers seek homes affiliated with its brands such as Ritz-Carlton, St. Regis, EDITION and W everywhere from Mexico to Malaysia and Boston to Bangkok. Marriott is the largest branded residential company in the lodging industry. With nearly 90 branded residential projects already open, the company has a pipeline of more than 60 additional signed and approved projects in locations ranging from resort destinations to gateway cities. In 2017 alone, the company signed 13 branded residential projects - setting an annual record. From gateway cities to emerging markets, Marriott's brands are flourishing where high-value real estate buyers work and play.

09:14 EDT Genius Brands signs agreements with KIDdesigns, Basic Fun! - Genius Brands has signed agreements with KIDdesigns on the development of a youth electronics line for the property, and Basic Fun!, who will develop a novelty toy line based on preschoolers' colorful superheroes. The announcement was made by Genius Brands' SVP of global licensing Lloyd Mintz.

09:11 EDT Delta Air Lines reports August traffic up 3.6%, capacity up 3.5% - Delta Air Lines reported operating performance for August 2018. The company carried 18.3M customers across its broad global network, a record for the month of August. Traffic, as measured by RPMs, was up 3.6% from the prior year. Capacity, as measured by ASMs, was up 3.5% year-over-year. Load factor of 88% compares to 87.9% in August 2017.

09:09 EDT Williams-Sonoma and Cadillac partner to bring Charter Oak restaurant to New York - Williams Sonoma announced a partnership with Cadillac to bring the first-ever East Coast pop-up of The Charter Oak since opening in June 2017, with three-Michelin starred Chef Christopher Kostow, to New York City, on September 20th and 21st.

09:07 EDT Amazon Fashion launches J.Crew Mercantile on Amazon - Amazon Fashion announces the arrival of J.Crew Mercantile on Amazon. For the first time, starting today customers in the U.S. shopping for fashion on Amazon have access to a wide selection of J.Crew Mercantile, further enhancing the robust fashion selection available on Amazon. This partnership is a natural extension of J.Crew's mission to be where people are shopping and is an exciting opportunity for Amazon Fashion to represent an iconic American brand.

09:05 EDT Walmart testing new Spark Delivery last-mile grocery delivery service - Walmart announced a new last-mile grocery delivery pilot, Spark Delivery. Spark Delivery is a crowd-sourced delivery platform that provides drivers with the ability to sign up for windows of time that work best for their schedule as well as Grocery Delivery order details, navigation assistance and more. Components of Spark are powered by Bringg, a leading delivery logistics technology platform. Walmart's team of personal shoppers shop for customers' orders. Spark Delivery engages the services of independent drivers who partner with Delivery Drivers, a nationwide firm who specializes in last-mile contractor management, to complete deliveries. Delivery Drivers manages recruiting, screening and background checks, payment, and accounting, among other services for drivers.

09:03 EDT Edgewell Personal Care to highlight strategy for growth, value creation - Edgewell Personal Care Company is presenting at the Barclays Global Consumer Staples Conference regarding the Company's overall strategy, key initiatives, financial results and priorities. The company said, "Highlights of the presentation include:Edgewell is well-positioned for the future, with a portfolio of competitive and profitable brands. Since the launch of Edgewell as a standalone publicly-listed company in July 2015, the Company's Core Wet Shave and Sun Care brands have gained market share in challenging categories. Edgewell is focused on launching innovative new products while executing on its strategic growth initiatives. These include growing sales and market share in e-retail and growth channels, expanding the Company's international footprint, building e-commerce and digital capabilities, and entering new growth categories through M&A. Edgewell is implementing Project Fuel to enhance shareholder value. Project Fuel is an enterprise-wide initiative to transform the Company's business and cost structure. The Company expects to achieve $225M in annual gross savings by the end of fiscal 2021 to fund growth, transformation and margin expansion. Reinvestment priorities include repositioning and growing Wet Shave, accelerating Sun and Skin Care growth, international expansion, and driving e-commerce and digital across the portfolio. Edgewell's strengthened Board and management team are focused on execution and value creation. Five new directors have been appointed to the Edgewell Board in the past three years, including two recent additions, Joe O'Leary and Gary Waring, who will be joining effective October 1, 2018. For the release announcing their appointments, see http://ir.edgewell.com/news-and-events. Edgewell has also strengthened its management team with key leadership changes over the past 16 months, including new appointments in marketing, e-commerce, operations and supply chain. Edgewell's Board and management team have the experience and skills to successfully execute the Company's strategy and have been and will remain open minded and committed to taking actions in the best interest of the Company and its stakeholders. Edgewell's annual strategic plan process included a comprehensive review of the business. The Board and management team, with the assistance of external advisors, conducted a comprehensive review of Edgewell's business segments in light of rapidly changing consumer, competitive and retail trends and their potential impact on future results. After assessing all value creation opportunities, the Board and management team concluded that Project Fuel is the best path to drive value creation for all stakeholders."

08:55 EDT Pfizer granted Breakthrough Therapy Designation from FDA for PF-06651600 - Pfizer's investigational oral Janus kinase 3 inhibitor PF-06651600 received Breakthrough Therapy designation from the FDA for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body. The Breakthrough Therapy designation for alopecia areata was supported by positive results from a Phase 2 study, which will be presented during the late-breaking news session at the 27th European Academy of Dermatology and Venerology Congress in Paris on September 15. Currently, there are no FDA-approved treatments for alopecia areata. Pfizer is also working with the EMA on the clinical development program for PF-06651600.

08:45 EDT TOP Ships announces reduced fees - TOP Ships announced that it has agreed with its manager to reduce related party fees starting January 1, 2019 as follows. Management fee for commercial and technical management will be reduced by 40% to $550 per vessel per day. Executive services fees will be reduced by 85% to $30,000 per month.

08:44 EDT Tesaro reiterates previously issued financial guidance for second half of 2018 - In a regulatory filing, Tesaro noted that the company is attending Citi's 13th Annual Biotech Day in Boston, Massachusetts on September 5. During a webcast "fireside chat" and other investor meetings at this event, the company expects to utilize a presentation including the JASPER clinical trial data, other information regarding its clinical trial activities, and other general business information. The presentation also reiterates the company's previously issued financial guidance for the second half of 2018, Tesaro stated.

08:41 EDT Attis Industries joint venture partner GS CleanTech files appeal in patent case - Attis Industries announced that its joint venture partner, GS CleanTech, a wholly-owned subsidiary of GreenShift, filed its appeal of intermediate judgments issued in CleanTech's pending patent litigation against corn ethanol producers for infringement of five of CleanTech's eleven issued corn oil extraction patents.

08:39 EDT Namaste announces 300% growth for August m-o-m revenue in Canadian marketplace - Namaste Technologies is pleased to announce that the company has achieved a 300% month-on-month growth rate in its Canadian marketplace, in comparison with August of 2017, and 50% growth globally. In the month of August of 2018, the company generated $1.65M in revenue which represents a 50% increase in revenue in comparison with August of 2017 after consideration of the loss of revenue due to Namaste divesting its US assets that were incorporated into its 2017 sales. The company has also achieved over 300% growth on its Canadian websites, which now includes over 17,000 customers.

08:36 EDT NuVasive announces launch of TLX 20 degree implant - NuVasive announced the launch of its TLX 20 degree expandable spinal interbody implant with a first-of-its-kind oblique profile designed for transforaminal lumbar interbody fusion procedures. This product launch is another step forward in the Company's strategy to build a comprehensive expandable portfolio to best support optimal clinical outcomes.The TLX 20 expandable implant's integrated auto-lock feature allows surgeons to incrementally customize expansion up to 20 degrees of oblique lordosis and tailor implant expansion based on a patient's clinical need, compared to many expandables in the market which only offer up to 15 degrees of lordosis. The implant profile is designed to optimally contour to a patient's interdiscal space to help maintain coronal alignment while achieving sagittal correction, an important aspect of desired patient outcomes that has been clinically validated through research and data from NuVasive's Integrated Global Alignment platform. In addition, the TLX 20 degree implant system includes a single, low-profile instrument to position, expand and post-pack the implant with bone graft, improving visualization into the disc space and surgical workflow. The implant also features increased tapering at the distal tip to aid insertion into a collapsed disc space, common among patients with degenerative disc disease, while minimizing the disruption to the surrounding anatomy.

08:34 EDT Cesca Therapeutics provides commercialization update for X-Series product line - Cesca Therapeutics announced that is has sold X-LAB and/or X-WASH systems to four initial institutions/entities, and expects to end 2018 with a significant increase in the number of new customers. Since the first formal exhibition of its X-Series platform in May 2018, the Company has received consistently positive feedback and interest in the product line. Cesca will include a commercialization update during its presentation at the upcoming HC Wainwright conference, on September 6, 2018. "Although sales of the X-Series instruments are one-time transactions, each results in recurring sales of single-use cartridges. We anticipate between 2,500 and 3,500 cartridge sales from customers acquired in 2018," stated CEO Chris Xu.

08:32 EDT Neurotrope, Nemours collaborate to initiate clinical trial in Fragile X syndrome - Neurotrope is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children to initiate a clinical trial in children with Fragile X Syndrome. The planned protocol for the pilot open-label trial will dose Fragile X patients from 8 to less than 18 years of age, using a dosing regimen similar to that being tested in AD patients. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. Fragile X is characterized by synaptic immaturity, cognitive impairment, and behavioral changes that currently have no effective therapeutics. The disorder is caused by transcriptional shutdown in neurons of the FMR1 gene product, the Fragile X mental retardation protein. Fragile X, a childhood neurological disorder that afflicts approximately 135,000 individuals in the U.S., is characterized by widespread loss of synaptic connections and occurs early in the neurological development process. Pre-clinical studies have shown that chronic treatment with Bryostatin-1 rescues young Fragile X mice from the disorder phenotypes, including normalization of most Fragile X abnormalities in: 1) hippocampal brain-derived neurotrophic factor expression; 2) postsynaptic density-95 levels; 3) transformation of immature dendritic spines to mature synapses; 4) densities of the presynaptic and postsynaptic membranes, and; 5) spatial learning and memory. Our pre-clinical results demonstrate that synaptic and cognitive function of young Fragile X mice can potentially be normalized through pharmacological treatment without down-regulation of mGluR5 and that Bryostatin-1-like agents may represent a novel class of drugs to treat the effects of Fragile X at a young age and in adults.

08:28 EDT RigNet reaches global master supply agreement with McDermott subsidiary - RigNet's (RNET) fast-track installation and differentiated end-to-end connectivity helped secure a global master supply agreement with a subsidiary of McDermott (MDR). RigNet provided McDermott with managed communication services and multiple over-the-top, or OTT, solutions to ensure their fleet of vessels is equipped with the most advanced communication systems available. RigNet was able to leverage its network of global support to fast-track the implementation of the project and install McDermott's entire global fleet to meet an aggressive mobilization timeline. RigNet installed and is providing fully-managed communications solutions that included a stabilized dual-band smart antenna that enables automatic switching between C-Band and Ku-Band networks.

08:26 EDT Sangamo reports 16 week reductions in urinary glycosaminoglycans in SB-913 study - Sangamo Therapeutics reported 16 week reductions in urinary glycosaminoglycans, a key biomarker of Mucopolysaccharidosis Type II disease pathophysiology, in Cohort 2 of the Phase 1/2 CHAMPIONS Study evaluating SB-913. SB-913 is a zinc finger nuclease in vivo genome editing product candidate being evaluated for the treatment of MPS II, also known as Hunter syndrome. In Cohort 2 at 16 weeks post-dosing, mean reductions were observed in total urinary GAGs, dermatan sulfate, and heparan sulfate of 51%, 32%, and 61%, respectively. The data were presented today at the 2018 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism being held in Athens, Greece. The CHAMPIONS Study is the first evaluation of an in vivo genome editing treatment in humans. The clinical trial is evaluating three separate doses of SB-913 over a planned 36 month study period. Today's presentation included early safety and efficacy results for Cohort 1 and Cohort 2, with two patients enrolled in each. Enrollment and dosing of Cohort 3 was recently completed. MPS II is a genetic lysosomal storage disease caused by deficiency of the iduronate-2-sulfatase enzyme which is needed to break down or recycle glycosaminoglycans dermatan sulfate and heparan sulfate. Without IDS enzyme, the GAGs accumulate in nearly all organs and body tissues. Chronic accumulation of GAGs inside cellular lysosomes results in cellular engorgement, organomegaly, tissue destruction, and organ system dysfunction. SB-913 is designed to treat MPS II by using Sangamo's ZFN genome editing technology to insert a new copy of the IDS gene into a precise location in the DNA of liver cells to enable a patient's liver to produce a continuous and stable supply of the missing human IDS enzyme. SB-913 is a single intravenous infusion of AAV6 vectors packaging ZFNs and a copy of the IDS gene. The ZFNs are designed to enter the cells as inactive DNA instructions in a format designed only for liver cells to unlock. Once "unlocked," the ZFNs then identify, bind to and cut the DNA in a specific location within the albumin gene. Using the cells' natural DNA repair processes, Sangamo believes liver cells can then insert the IDS gene at that precise location. Driven by the strong albumin promoter, the IDS gene would then express IDS enzyme and would be taken up by tissues and cells where the enzyme breaks down dermatan sulfate and heparan sulfate GAGs into individual sugars. Safety data presented today were collected and analyzed as of July 10, 2018 and included information on the first five subjects. In all subjects, administration of SB-913 was generally well-tolerated. There were no serious adverse events reported as related to SB-913. The majority of adverse events reported were mild and resolved without treatment. All AEs reported as related to SB-913 were mild, resolved without treatment, and did not show evidence of dose dependence. Two SAEs were reported and both were determined by the site investigator to be due to primary MPS II disease and unrelated to SB-913 treatment. No persistent transaminitis was observed in any subject.

08:23 EDT Volkswagen CFO says 'no substance' to rumors of talks to invest in Tesla - Volkswagen (VLKAY) CFO Frank Witter said earlier in an interview on Bloomberg TV that having a trade agreement in the NAFTA area is "important" as automakers need "reliable conditions" and "stability." Witter also said during the interview that "there is no substance" to rumors that Volkswagen was involved in talks to invest in Tesla (TSLA) as part of the latter's exploration of a plan to go private. Witter said the go private talks were "entirely up to Tesla and we were not part of it." Witter added that VW has "a lot of respect for Tesla and Elon Musk" and that "we should and do take them as a serious competitor," but that VW "relies and trusts in our ability." Reference Link

08:20 EDT Edgewell Personal Care appoints Joseph O'Leary, Gary Waring to board - Edgewell Personal Care Company announced the appointment of Joseph "Joe" D. O'Leary and Gary K. Waring to the Company's Board of Directors, effective October 1, 2018. With these new appointments, Edgewell gains Directors with expertise in retail, eCommerce, supply chain, acquisitions, divestitures, and restructuring, as well as regulatory and audit committee expertise. The Edgewell Board will now comprise 10 directors, nine of whom are independent. Mr. O'Leary will serve on the Nominating and Executive Compensation Committee of the Board and Mr. Waring will serve on the Audit Committee of the Board. Joseph O'Leary is the former President and COO of Petsmart. Gary Waring is an accounting professional who retired in July 2017.

08:19 EDT Trovagene announces method for predicting response to Onvansertib - Trovagene announced it has developed a method for predicting response to treatment by measuring the ability of Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 inhibitor, to inhibit PLK1 in patients with Acute Myeloid Leukemia. Trovagene is a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of solid tumor cancers and leukemias/lymphomas. PLK1 uniquely phosphorylates translational control tumor protein to form pTCTP and inhibition of this enzymatic activity by Onvansertib appears to be predictive of patient response to treatment. In the ongoing Phase 1b/2 open label clinical trial in AML, PLK1 inhibition is being assessed 3-hours following administration, at the approximate peak concentration of Onvansertib. In the first six patients treated, the greatest target engagement, or inhibition of PLK1, was observed in the three patients who showed a response to treatment. Trovagene has filed a U.S. patent application with the United States Patent and Trademark Office to protect its method for evaluating responsiveness of a cancer to a Polo-like Kinase 1 (PLK1) inhibitor by determining the ability of the PLK1 inhibitor to inhibit phosphorylation of a unique target of PLK1 in cells of the cancer.

08:17 EDT BioLife Solutions increases ownership in SAVSU Technologies to 44% - BioLife Solutions announced that it has increased its ownership of SAVSU Technologies from approximately 31% to 44% with a $5M investment. SAVSU will use the investment to scale up its operations and inventory to support increased demand for its evo Dry Vapor Shippers and other precision temperature controlled shipping containers for cell and gene therapies. The 18-month purchase option provides BioLife, at its sole discretion, with the right to acquire the 56% of SAVSU not already owned, for the greater of 1,000,000 shares of BioLife common stock, or approximately $23M of BioLife common stock, calculated on the day of exercise. If BioLife exercises the purchase option in the future, 75% of the shares would be issued at closing, with the remaining 25% issued upon the achievement of specific revenue milestones.

08:14 EDT BioCardia announces additional data from Phase III CardiAmp heart failure trial - BioCardia announced that additional data from the open label, roll-in cohort of the ongoing Phase III CardiAMP Heart Failure Trial are expected to be presented at three upcoming fall cardiovascular congresses. The CardiAMP-HF Trial is a study of the company's autologous, investigational CardiAMP stem cell therapy for the treatment of heart failure developed following a heart attack. Positive six-month outcomes from the first 10 patients were published online in Circulation Research in late August and are expected to be published in print in the September 28, 2018 issue. The CardiAMP-HF Trial is a 260-patient biotherapeutics study currently enrolling at up to 40 centers in the U.S. as an FDA-approved pivotal study. The Center for Medicare and Medicaid Services has approved reimbursement for the trial, which also has grant support from the Maryland Stem Cell Research Fund. CardiAMP cell therapy uses a patient's own (autologous) bone marrow cells to potentially stimulate the body's natural healing response through a minimally-invasive, catheter-based procedure.

08:12 EDT Tyme Technologies exceeds enrollment expectations for Phase 2 SM-88 trial - Tyme Technologies announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion of the company's Phase II trial in metastatic pancreatic cancer ahead of the trial's anticipated timeline. Management maintains its guidance that it will share interim data in early 2019, when it expects that the majority of Stage 1 subjects could have both initial and confirmatory CT/PET scans for RECIST and PERCIST assessment of tumor response. All 31 subjects were randomized to one of the two doses, and an additional 19 subjects have consented and are in final screening to be randomized. Based on enrollment patterns to date, Tyme expects that approximately two-thirds of the currently consented subjects will successfully complete screening and be randomized to drug dosage, which would provide total enrollment greater than the 36 subjects initially sought.

08:10 EDT Cantel Medical announces plan to expand facility in Minnesota - Cantel Medical Corp announced that it has recently purchased a new office building at 9800 59th Ave. N. in Plymouth, Minnesota that has capacity for approximately 600 employees. The company is consolidating four of its locations into a single four-story, 159,000-square-foot building. Cantel plans to occupy the new building beginning in March 2019.

08:09 EDT Criteo names Ryan Damon general counsel - Criteo announced the appointment of Ryan Damon as General Counsel. In his new role, Damon will oversee the legal, data privacy and government relations functions as part of Criteo's continued commitment to global growth and innovation. Damon will lead Criteo's mission to shape the future of compliance in an evolving data and technology driven environment. He will report directly to JB Rudelle, Criteo's CEO. Prior to his role at Criteo, Damon served as SVP and General Counsel at Riverbed Technology.

08:07 EDT Hawaiian Airlines sees FY18 ASM up 5%-7% - The Company has also revised certain of its expectations for the full year ending December 31, 2018 that were previously provided on July 24, 2018.Specifically, the Company lowered its expectations for full year ASMs and gallons of jet fuel consumed following the planned suspension of its thrice-weekly nonstop service between Honolulu's Daniel K. Inouye International Airport and Beijing Capital International Airport effective mid-October 2018. The Company's expectations for full year operating costs per ASM excluding aircraft fuel and special items remain unchanged. The company sees Available seat miles Up 5.0 - 7.0% compared to previous guidance Up 5.5 - 7.5%. Sees Gallons of jet fuel consumed Up 3.5 - 5.5% compared to previous guidance of Up 4.0 - 6.0%.

08:07 EDT Arcadia Biosciences files challenge of Arista's Resistant Starch wheat patents - Arcadia Biosciences has filed a notice of appeal to the U.S. Court of Appeal for the Federal Circuit and a lawsuit in the U.S. District Court for the Southern District of New York against Arista Cereal Ingredients and two of its affiliates. The actions are related to Arcadia's high-fiber Resistant Starch wheat. The Federal Circuit notice of appeal challenges the recent decision by the Patent Trial and Appeal Board on Arcadia's RS GoodWheat technology, adopting a claim construction that resulted in dismissal of Arcadia's interference action pertaining to Arista's U.S. Patent No. 9,357,722. Arcadia believes that the PTAB's claim construction was incorrect because it failed to follow applicable standards and adopted a claim construction inconsistent with Arista's own statements on the scope of that patent. The Southern District of New York suit against Arista and its affiliates Vilmorin and Limagrain seeks correction of inventorship on key Arista patents and other remedies. The lawsuit asserts claims against those defendants arising out of breaches of a confidentiality agreement with Arcadia and claims that Arcadia scientists should be added as sole or joint inventors on the challenged patents.

08:05 EDT Hawaiian Holdings sees Q3 operating RASM flat to down 2% - The Company has revised certain of its expectations for the third quarter ending September 30, 2018 that were previously provided on July 24, 2018.Specifically, the Company lowered its expectations for third quarter operating revenue per available seat mile as a result of service disruptions, passenger cancellations and booking interruptions stemming from Hurricane Lane. The company sees operating revenue per ASM Flat - Down 2.0% compared to its previous guidance of Down 1.5% - Up 1.5%.

08:02 EDT CACI awarded $75M task order for U.S. forces engineering support - CACI was awarded a task order with a ceiling value of $75M by Space and Naval Warfare Systems Center Atlantic to deliver defense health readiness engineering support for the U.S. Navy, U.S. Marine Corps, and U.S. Air Force. The five-year task order was awarded under the SeaPort-e vehicle and represents continuing work for CACI in its Health market area.

07:43 EDT Howard Hughes acquires two Class-A office buildings in Texas - The Howard Hughes Corporation announced that, in an off-market transaction, it has acquired two vacant, Class-A office buildings immediately adjacent to its Hughes Landing development in the renowned master planned community of The Woodlands. The company purchased the four- and six-story buildings totaling 257,025 of rentable square feet with spectacular views of Lake Woodlands, along with excess land which allows for the development of an additional office building, for $53M. The buildings, which were completed in 2002 and 2012, had been owned and occupied by the seller and were subject to deed restrictions that The Howard Hughes Corporation holds the unilateral right to modify, providing potential upside to the acquisition. The Howard Hughes Corporation intends to re-tenant these buildings as soon as possible upon acquisition.

07:41 EDT Dermira updates Qbrexza launch readiness - Dermira announced several updates related to the upcoming launch and availability of Qbrexza cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza was approved by the FDA in June. Qbrexza is expected to be available in pharmacies nationwide beginning on October 1. Qbrexza will launch with a list price of $550 per 30-day supply. To ensure that patients suffering from primary axillary hyperhidrosis have access to the therapy, Dermira has been working with leading national insurers to secure coverage for Qbrexza. Two of the largest pharmacy benefit managers in the United States have agreed to provide immediate coverage of Qbrexza through their national formularies, effective October 1. To date, Dermira has secured contracted coverage for approximately 34% of the total U.S. commercial lives to date, with the goal of securing more than 50% coverage by January 1, 2019.

07:37 EDT Tactile Systems awarded new FSS contract for Flexitouch systems - Tactile Systems announced that the company has been awarded a new federal supply schedule, or FSS, contract for its Flexitouch systems by the National Acquisition Center, U.S. Department of Veterans Affairs, or VA. The FSS contract includes the company's latest-generation Flexitouch system, Flexitouch Plus. It facilitates access to the Flexitouch Plus system for VA clinicians and staff, as well as their patients, and provides pre-negotiated pricing, terms and conditions that streamline the buying process. The new FSS contract became effective on September 1.

07:35 EDT Nielsen names David Anderson CFO - Nielsen's Board of Directors announced that David Anderson joined Nielsen effective immediately and will become CFO as of September 10, 2018. At Nielsen, Anderson will oversee all financial functions and will play an active role in communications with shareholders and analysts. Anderson succeeds Jamere Jackson, who served in the role since 2014 and has resigned to pursue an opportunity outside of the company. Previously, Anderson served as CFO of diversified manufacturer ITT Industries, Inc. and of Newport News Shipbuilding, where he led the effort to establish the company as a standalone publicly traded entity.

07:32 EDT ADMA Biologics announces BLA resubmission for RI-002 targeted for Q3 - Adam Grossman, president and CEO of ADMA Biologics said, "We are excited to finally be in a position to resubmit our Biologics License Application ("BLA") for RI-002 during the third quarter of 2018, which we believe is a needed Intravenous Immune Globulin ("IVIG") option for patients who suffer with Primary Humoral Immunodeficiency Disease ("PIDD"). We will announce related information pertaining to RI-002's BLA filing when the Company receives correspondence from FDA."

07:27 EDT ADMA Biologics announces improved FDA compliance for manufacturing facility - ADMA Biologics announced that the FDA inspection database classification website has been updated and confirms ADMA's compliance status has improved to voluntary action indicated.

07:19 EDT Summit Therapeutics nominates SMT-571 as lead candidate from gonorrhoea series - Summit Therapeutics announced that it has nominated SMT-571 as its lead clinical candidate from its first gonorrhoea series. New mechanism antibiotics are important in the fight against gonorrhoea, as the pathogen is becoming increasingly resistant to the only recommended treatment option. Just last week, the US Centers for Disease Control and Prevention, or CDC reported preliminary data that gonorrhoea cases in the U.S. increased by 67% between 2013 and 2017 and with resistant cases on the rise, the CDC stated that additional treatment options for gonorrhoea are urgently needed. In in vitro studies, SMT-571 killed N. gonorrhoeae through a novel target involved in cell division, which was identified using Summit's Discuva Platform. SMT-571 has demonstrated potent in vitro activity against clinical isolates of N. gonorrhoeae, including multi-drug resistant strains. With the nomination, Summit is progressing SMT-571 into investigational new drug, or IND, enabling studies. The company plans to initiate a Phase 1 clinical trial of SMT-571 in the second half of 2019. The development SMT-571 is supported by a CARB-X award worth up to $4.5M and granted in July of this year, which covers its development through the end of the Phase 1 clinical trial subject to certain milestones being met.

07:16 EDT Group 1 Automotive expands board to ten directors - Group 1 Automotive announced the appointment of Anne Taylor, a former top executive and Vice Chairman at Deloitte, to its board of directors, effective immediately. Additionally, the company expanded the board to a total of 10 directors to accommodate a transition period in preparation for several director retirements over the next two to three years, based on the company's retirement age policy for its board. Ms. Taylor's appointment brings the total number of independent directors to eight, in addition to the company's two non-independent directors.

07:15 EDT MediWound receives marketing authorization for NexoBrid in Russia - MediWound announced receipt of authorization from the Ministry of Health in Russia to market and distribute NexoBrid for the removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns. Genfa Medica, MediWound's exclusive distribution partner in Russia, received the marketing authorization and intends to launch NexoBrid in Russia in the first half of 2019. This regulatory approval builds upon NexoBrid's marketing authorization from the European Medicines Agency for the same indication and again validates MediWound's strategy of using the EMA approved registration file for seeking approval in different international markets around the globe.

07:13 EDT Canadian National will acquire 60 additional locomotives from GE Transportation - GE (GE) Transportation announced that Canadian National (CNI) will acquire 60 additional locomotives, expanding the class I's 200-unit order placed in December 2017. Similar to CN's 2017 purchase, this order includes Tier 4 Evolution Series locomotives equipped with GE Transportation's GoLINC Platform, Trip Optimizer System and Distributed Power LOCOTROL eXpanded Architecture to maximize train effectiveness and efficiency. These solutions are part of GE Transportation's train performance product suite, which optimizes power distribution, train handling, brake control and fuel utilization. The new purchase also includes a multi-year service agreement that supports CN's long-term operational needs.

07:10 EDT Evogene announces milestone in herbicide pipeline - Evogene announced a significant milestone in its next generation herbicide pipeline. Evogene's Ag-Chemicals division demonstrated biological proof in lab assays that Evogene discovered molecule families bind to essential target proteins representing new mode of actions, or MoA's. These next generation herbicide candidates have the potential to overcome growing weed resistance, with improved efficacy while maintaining a standard of safety since they have now been proven to address novel target proteins not present in humans.

07:08 EDT DarioHealth appoints Olivier Jarry president, CCO - DarioHealth announced that Olivier Jarry, a prominent global life sciences and consumer health executive, has joined the company as president and chief commercial officer. Jarry will be based in the U.S. and will lead DarioHealth's efforts relating to global revenue generation including B2B sales and data monetization. As Global Business Head at Bayer (BAYRY) Diabetes Care, he managed in excess of $1.4B in sales. At Novartis (NVS) he headed four regions: Europe, India, Latin America, and Asia Pacific in consumer health products, generics and vaccines.

07:06 EDT Check-Cap receives approval from Israeli Ministry of Health for C-Scan sales - Check-Cap announced it has received approval from the Israeli Ministry of Health, the Medical Device Division, to initiate commercial sales in Israel of the C-Scan system that received CE Mark approval in January 2018. The indication of use for the C-Scan system as provided in the AMAR approval are as follows: "The C-Scan system is intended to provide structural information on the endoluminal surface of the colon. It may be used to screen for colonic suspicious findings in adults at average-risk for CRC who are not candidates for colonoscopy or who decline colonoscopy." The AMAR approval is valid until February 28, 2019 and its extension is subject to certain conditions detailed in the AMAR approval and the requirements of the Israeli Ministry of Health.

07:04 EDT Ciena to acquire DonRiver - Ciena has entered into a definitive agreement to acquire privately-held DonRiver, a global software and services company specializing in federated network and service inventory management solutions within the service provider Operational Support Systems environment. With the addition of DonRiver's federated network and service inventory management solutions, Ciena's Blue Planet capabilities will extend beyond network orchestration and control to also provide a unified inventory view of all elements across a provider's network. The transaction is expected to close during Ciena's Q4.

07:02 EDT ITUS, Moffitt Cancer Center announce scheduling of Pre-IND meeting with the FDA - ITUS Corporation and its research partner, Moffitt Cancer Center announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018. The meeting is to discuss numerous aspects of the planned clinical trial of their CAR-T therapy for ovarian cancer.

07:02 EDT Canadian National orders 60 more locomotives from GE Transportation - GE Transportation (GE) announced that CN (CNI) will acquire 60 additional locomotives, expanding the class I's 200-unit order placed in December 2017.

06:53 EDT Loxo Oncology announces breakthrough therapy designation for LOXO-292 from FDA - Loxo Oncology announced that the FDA has granted breakthrough therapy designation to LOXO-292, a selective RET inhibitor, for the treatment of patients with metastatic RET-fusion-positive non-small cell lung cancer who require systemic therapy and have progressed following platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy; and for the treatment of patients with RET-mutant medullary thyroid cancer who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options. The LOXO-292 breakthrough therapy designation was based on data from the ongoing global Phase 1/2 LIBRETTO-001 clinical trial. In 2019, the company plans to provide an update on the overall long-term LOXO-292 clinical development plan, based on feedback from global regulators.

06:48 EDT Crescent Point Energy appoints Robert Heinemann as Chairman of the Board - Crescent Point's Chairman of the Board Peter Bannister has stepped down, with Robert Heinemann assuming the role. Heinemann has served the Board since 2014 and possesses more than 30 years of executive oil and gas experience and leadership, including acting as a director on various company boards as well as his prior position as President and CEO of Berry Petroleum Co. from 2004 to 2013. The appointment of the Chairman of the Board and CEO follow Crescent Point's previously disclosed governance review that commenced in late 2017 and includes Board and executive succession planning. Bannister and Gerald Romanzin will each be retiring from the board at the company's 2019 annual general meeting. Following the company's 2019 AGM, Crescent Point's board will have undergone a complete renewal since inception.

06:44 EDT Crescent Point appoints Craig Bryksa as CEO, adopts transitional plan - Crescent Point Energy appointed Craig Bryksa as CEO, and adopted a new transition plan. The transition plan includes focusing the company's asset base by pursuing significant upstream asset divestitures; targeting a net debt reduction of over $1.0B by year end 2019, through a return-focused budget and asset dispositions; identifying certain midstream assets for potential monetization; reducing workforce by approximately 17% to achieve an annual total expense savings of over $50M. Crescent Point expects to optimize its capital allocation process and overall efficiencies by focusing its asset base and has identified the Viewfield, Shaunavon and Flat Lake resource plays as key focus areas. The company also plans to continue advancing its emerging and earlier stage resource plays in the Uinta Basin and East Shale Duvernay. These areas accounted for approximately 70% of Crescent Point's Q2 production. The company's remaining assets account for approximately 50,000 boe/d of its current production. The Company is targeting a net debt to funds flow from operations below 1.3 times in a commodity price environment of $65/bbl WTI.

06:35 EDT Quarterhill company Wi-LAN renews license agreement with Doro - Quarterhill company Wi-LAN has signed a multi-year running royalty license agreement with Doro AB. The licensed patents relate to handset technology. The consideration paid to WiLAN and all other terms of the license agreement are confidential.

06:16 EDT Dicerna's DCR-PHXC for hyperoxaluria achieves preliminary proof-of-concept - Dicerna announced preliminary proof-of-concept data from its ongoing PHYOX Phase 1 clinical trial. A single-dose administration of DCR-PHXC, the company's lead GalXC product candidate, brought urinary oxalate levels into the normal range or near-normal range in a majority of the eight assessed patients with primary hyperoxaluria type 1 and type 2. All of the assessed patients experienced substantial and clinically significant reductions in urinary oxalate. The interim PHYOX data constitute preliminary clinical proof of concept for DCR-PHXC. The investigational agent was safe and well-tolerated during the period of initial observation. The interim data are consistent with an anticipated once-quarterly administration. Dicerna intends to present a detailed data readout from the PHYOX trial in Q4, and plans to initiate a registration trial for DCR-PHXC pending regulatory feedback in 1Q19. Dicerna is investigating DCR-PHXC for the treatment of all forms of PH, a family of severe, rare, inherited disorders of the liver that often result in kidney failure. The company initiated the PHYOX trial in normal healthy volunteers in 4Q17 and dosed the first patient with PH in May.

06:11 EDT U.S. Concrete awarded permit for increase in aggregates sent to California - U.S. Concrete announced that its wholly owned subsidiary, Polaris Materials, has obtained the necessary permits to increase the amount of aggregates it imports at its terminal located in Long Beach, California. As a result of the new permit, Polaris is now able to deliver up to 2M tons of highly specified aggregates annually, effectively doubling its throughput capacity in supply-constrained Southern California. U.S. Concrete acquired the Long Beach Terminal as part of its acquisition of Polaris in November 2017, which marked its entry into the Southern California market. By increasing its aggregates permitted volume, the company can expand its project capacity and scope.

06:08 EDT Hercules Capital seeking stockholder approval to reduce asset coverage to 150% - Hercules Capital conducted an extensive review of the Small Business Credit Availability Act which permits Hercules to choose to reduce its asset coverage requirement, subject to either receipt of approval from the Board, which would defer any change for a period of one year, or approval by its stockholders, which would immediately reduce its asset coverage requirements to 150%. The board determined to seek stockholder approval to accelerate the application of the reduced asset coverage requirements to the company at a special stockholder meeting to be held on December 6. In addition, the board approved the application of the modified asset coverage requirements to be effective one year after such board approval and as a result, the company's asset coverage requirements for senior securities will be changed from 200% to 150%, effective September 4, 2019. However, if the stockholder proposal is passed at the Special Meeting, the company would be subject to the modified asset coverage requirements the day after the Special Meeting.

05:58 EDT Nevsun Resources to be acquired by Zijin Mining for $1.41B - Nevsun Resources announced that the parties have entered into a definitive agreement pursuant to which Zijin will make a take-over bid to acquire all of the issued and outstanding shares of Nevsun for C$6.00 per share in cash. The Offer is valued at US$1.41B. The cash consideration of C$6.00 per share represents a premium of 57% over Nevsun's unaffected closing price of C$3.82 on May 7, 2018, the day Lundin Mining Corporation first publicly announced its intention to acquire Nevsun. In addition, the Offer is C$1.25 per Nevsun share, or 26%, more than the C$4.75 per share hostile take-over bid for Nevsun launched by Lundin on July 26, 2018. The Offer is not subject to any financing conditions. Details of the Offer will be included in a take-over bid circular that Zijin will file and mail to Nevsun shareholders in the coming days, but no later than September 18, 2018. Nevsun's Board of Directors unanimously recommends that Nevsun shareholders tender their shares to ACCEPT the Offer. The basis for this recommendation will be included in a Nevsun Directors' Circular that will be filed and mailed to Nevsun shareholders concurrently with the filing of the Zijin take-over bid circular. Nevsun's board continues to recommend that Nevsun shareholders REJECT the hostile take-over bid launched by Lundin on July 26, 2018 and NOT tender their shares to the Lundin offer, which will expire on November 9, 2018. Nevsun's board of Directors had previously rejected the hostile bid from Lundin on the grounds that it, among other reasons, ignored the fundamental value of Nevsun's assets. Following the launch by Lundin of its hostile bid, a special committee of Nevsun's independent directors, with the assistance of Nevsun's advisors, initiated a review of all value-maximizing alternatives, including, but not limited to, an acquisition of all issued and outstanding Nevsun shares. This process has involved a number of global parties undertaking comprehensive due diligence on Nevsun. The Offer is a result of this full strategic alternative review process. Nevsun's Board of Directors and the Special Committee concluded that the Offer currently represents the best alternative available to Nevsun and provides Nevsun shareholders with the highest value proposition.

05:42 EDT DBV announces additional Phase I data in pertussis toxin study - DBV Technologies, the Geneva University Hospitals and BioNet-Asia presented new data from a Phase I study evaluating the safety and immunogenicity of boosting young adults against pertussis toxin with an investigational epicutaneous patch containing recombinant PT. The new results, which were presented at the European Congress of Immunology in by Dr. Olga Chatzis and Prof. Claire-Anne Siegrist, highlighted data from two additional cohorts showing that following skin preparation with an epidermal laser, anti-PT booster responses elicited by Viaskin-PT were comparable to those elicited by Boostrix dTpa, an injectable approved booster vaccine, DBV said in a statement. In March 2017, data from this study reported no detectable immunogenicity signal following the application of Viaskin-PT on intact skin, it added. Data presented showed favorable safety and immunogenicity responses in healthy adults who received two applications of Viaskin-PT following skin preparation with an epidermal laser, DBV said. No serious adverse events were reported. The company "continues to evaluate these positive proof of concept results to determine potential next steps in vaccination."

05:32 EDT Juniper expands partnership with Ericsson - Juniper Networks (JNPR) announced it has expanded its 18-year partnership with Ericsson (ERIC) to deliver a comprehensive end-to-end 5G solution leveraging each company's complementary portfolios. Together, the companies are now offering service providers a complete 5G transport network solution with single pane of glass visibility to manage the new requirements of next-generation mobile service delivery. This deepened partnership aims to offer service providers a complete solution from radio to core for new-service delivery while managing mounting complexity. 5G is expected to be a game changer for the next generation of business and consumer services, but the increase in connectivity, network traffic and customer expectations will likely create new challenges for managing the mobile transport network in a cost-effective way. Evolving 5G use cases, including connected cars, AR/VR and 8K video streaming, and the associated 5G radio requirements needed to support these diverse applications can place additional demands across the network. Capacity, connectivity, latency, synchronization, reliability and security needs will all require tighter integration between the 5G radio, core and transport layers of an end-to-end mobile network. As part of this deepened partnership, Juniper will utilize Ericsson's go-to-market for mobile opportunities and Ericsson will include Juniper's solutions for edge, core and security as part of its end-to-end 5G transport portfolio.

05:29 EDT Autoliv chairman Jan Carlson sold 42,589 shares of common stock on Aug. 31 - Autoliv announced that Jan Carlson, the Chairman of Autoliv's board, sold a portion of his shares of Autoliv common stock on August 31. Following the sale of 42,589 shares, Carlson owns 71,727 shares of Autoliv common stock, including shares of common stock underlying unvested restricted stock units. Carlson remains a committed long-term stockholder of Autoliv and made the sale to rebalance his investment portfolio to reflect his current executive positions following the spin-off of Veoneer. The sale was reported in filings with the SEC and the Swedish Financial Supervisory Authority according to current regulations.

05:25 EDT Hutchison China MediTech announces approval of fruquintinib capsules in China - Hutchison China MediTech announces that fruquintinib capsules have been granted approval for drug registration by the National Medical Products Administration of China for the treatment of metastatic colorectal cancer, or CRC, patients, who have failed at least two prior systemic antineoplastic therapies including fluoropyrimidine, oxaliplatin and irinotecan, with or without prior use of anti-vascular endothelial growth factor or anti-epidermal growth factor receptor therapies. Fruquintinib is a highly selective and potent small molecule oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 designed to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Fruquintinib capsules are to be marketed in China under the brand name Elunate. The approval is based on results from the Phase III FRESCO trial, which were presented at the American Society of Clinical Oncology 2017 Meeting and published in the JAMA in 2018.

05:20 EDT Celyad doses first colorectal cancer patient with CYAD-01 - Celyad announced the successful injection of the first patient under the amended protocol of the THINK trial, which assesses treatment with CYAD-01 after a non-myeloablative preconditioning chemotherapy regimen of cyclophosphamide and fludarabine in refractory metastatic colorectal cancer patients.